Samuel Waxman Cancer Research Foundation & Mount Sinai to Collaborate Against the Rising Incidence of Cancer Due to Aging
The Tisch Cancer Institute (TCI) at Mount Sinai and the Samuel Waxman Cancer Research Foundation (SWCRF) are launching a unique research program that will fund collaborations between TCI physician-scientists and colleagues from other established cancer research institutions to address the rising rates of cancer due to aging around the world.
The partnership will enhance the impact of both TCI and SWCRF through cross-institutional, cutting-edge research on abnormal gene function that causes cancer in order to uncover the link between aging and cancer and identify targeted therapies.
Both organizations will contribute equally to this pivotal, two-year, $1 million research program. And work together to prioritize, evaluate, and award research grants submitted for review by both TCI-affiliated and non-TCI-affiliated scientists throughout the two-year term of this collaboration, which starts this year.
“Science works better with collaboration,” says Samuel Waxman, MD, CEO and Founder of the Samuel Waxman Cancer Research Foundation and Distinguished Service Professor of Medicine (Hematology and Medical Oncology), and Oncological Sciences, at The Tisch Cancer Institute at Mount Sinai. “This model will provide an excellent opportunity to cast a wider net and connect investigators and labs who may not typically work together with the dual aim: investigate why aging in particular makes the body more susceptible to cancer and develop new, effective, and less toxic treatments for age-related cancers.”
The partnership with TCI and SWCRF comes at a pivotal time as aging increasingly becomes a leading risk factor for cancer. Older adults are a rapidly growing segment of the U.S. and global population, and it has been well documented that the incidence of cancer has continued to rise in people over 65. It is evident that a deeper understanding of the biological changes connected to aging in relation to the biology of cancer are required to understand and address the onset and trajectory of cancer.
“Our partnership with SWCRF will showcase our shared strengths in aging and cancer research,” says Ramon E. Parsons, MD, PhD, Director of TCI, Ward-Coleman Chair in Cancer Research, and Chair of Oncological Sciences at Icahn Mount Sinai. “We are proud that this concerted effort will help us deliver on our joint mission of providing the best in care and treatment for anyone diagnosed with cancer.”
Dr. Parsons added, “Our goal is to continue to build upon the great foundation of cancer research that has already been established by TCI at Mount Sinai and SWCRF. Cancer is complicated, and our collaboration will allow us to pick the right projects and bring together the best people to focus on this devastating disease.”
TCI has earned an indelible reputation as a leading cancer center thanks to its integrated, collaborative approach to cancer care, which has attracted renowned physicians and scientists whose expertise continues to elevate the work of the Institute. TCI has earned Designated Cancer Center status from the National Cancer Institute (NCI)—a program recognizing centers around the country that meet the rigorous standards for state-of-the-art cancer research—for a second consecutive five-year cycle. In 2019 alone, TCI engaged in 50 collaborations with other NCI-designed cancer centers. It also encompasses more than 80 renowned physicians and scientists whose expertise continues to propel the Institute’s work resulting in innovative new clinical trials that have led to new and innovative cancer treatments.
SWCRF was founded in 1976 by Samuel Waxman, MD, who serves as the Distinguished Service Professor for Medicine (Hematology and Medical Oncology), and Oncological Sciences, at the Icahn School of Medicine at Mount Sinai. For more than 45 years, SWCRF has been focused on eradicating cancer through funding ongoing collaborative, cross-institutional research around abnormal gene function to lay the groundwork for developing minimally toxic treatments for all patients with cancer. Since its inception, SWCRF has invested more than $100 million in cancer research to support the work of more than 200 researchers across the globe.
About the Mount Sinai Health System: The Mount Sinai Health System is New York City’s largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai advances medicine and health through unrivaled education and translational research and discovery to deliver care that is the safest, highest-quality, most accessible and equitable, and the best value of any health system in the nation. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture ambulatory surgery centers; more than 415 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. The Mount Sinai Hospital is ranked on U.S. News & World Report’s “Honor Roll” of the top 20 U.S. hospitals and is top in the nation by specialty: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 in Ophthalmology. Mount Sinai Kravis Children’s Hospital is ranked in U.S. News & World Report’s “Best Children’s Hospitals” among the country’s best in four out of 10 pediatric specialties. The Icahn School of Medicine is one of three medical schools that have earned distinction by multiple indicators: ranked in the top 20 by U.S. News & World Report’s “Best Medical Schools,” aligned with a U.S. News & World Report “Honor Roll” Hospital, and No. 14 in the nation for National Institutes of Health funding. Newsweek’s “The World’s Best Smart Hospitals” ranks The Mount Sinai Hospital as No. 1 in New York and in the top five globally, and Mount Sinai Morningside in the top 20 globally.
About the Samuel Waxman Cancer Research Foundation (SWCRF): The Samuel Waxman Cancer Research Foundation is an international organization dedicated to curing and preventing cancer. The Foundation is a pioneer in cancer research and its mission is to eradicate cancer by funding cutting-edge research that identifies and corrects abnormal gene function that causes cancer and develops minimally toxic treatments for patients. Through the Foundation’s collaborative group of world-class scientists, the Institute Without Walls, investigators share information and tools to speed the pace of cancer research. Since its inception in 1976, the Samuel Waxman Cancer Research Foundation has awarded more than $100 million to support the work of more than 200 researchers across the globe. For more information, visit www.waxmancancer.org.